UCLA scientists found that cat allergen immunotherapy works better and faster when combined with the monoclonal antibody tezepelumab. The work was published in the Journal of Allergy and Clinical Immunology.
The study involved 121 people aged 18 to 65 years. Patients were randomly assigned to receive either tezepelumab and allergen immunotherapy or immunotherapy alone. Allergen exposure was administered by nasal spray and tezepelumab was injected.
Control groups received placebo injections, either a placebo spray or a double placebo. After 48 weeks, participants who received both treatments had 36% less rhinitis symptoms than those who received standard treatment. One year later, the difference between the symptoms in the two groups was 24%.
The findings were confirmed by immunological analyses.
Tezepelumab blocks the TSLP protein, which is released by cells in the nose, lungs, intestines, and skin upon contact with an allergen. TSLP helps to activate the immune response, which in case of cat allergy leads to rhinitis symptoms.
Allergen immunotherapy is long-term exposure to allergens to reduce sensitivity to them in people with allergic rhinitis or asthma.
However, the method does not work for everyone, and the course of treatment takes up to three years.
Some animals have played an important role in the development of medicine. Why without frogs, dogs and pigs it would be completely different, find out in the gallery:
Read also: How to stay healthy in autumn: instructions. Watch the video:
” source=”viqeo” data-logger=”ArticleContent_embed_viqeo”>
Found an error? Select it and press Ctrl+Enter.
